RU2656186C2 - Вирус гриппа с и вакцина - Google Patents
Вирус гриппа с и вакцина Download PDFInfo
- Publication number
- RU2656186C2 RU2656186C2 RU2014134850A RU2014134850A RU2656186C2 RU 2656186 C2 RU2656186 C2 RU 2656186C2 RU 2014134850 A RU2014134850 A RU 2014134850A RU 2014134850 A RU2014134850 A RU 2014134850A RU 2656186 C2 RU2656186 C2 RU 2656186C2
- Authority
- RU
- Russia
- Prior art keywords
- virus
- influenza
- sample
- swine flu
- seq
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 13
- 241000713297 Influenza C virus Species 0.000 title abstract description 32
- 208000015181 infectious disease Diseases 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 24
- 201000010740 swine influenza Diseases 0.000 claims abstract description 18
- 230000003321 amplification Effects 0.000 claims abstract description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 5
- 239000013615 primer Substances 0.000 claims abstract 4
- 241000124008 Mammalia Species 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 229920001184 polypeptide Polymers 0.000 claims abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 3
- 239000003155 DNA primer Substances 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 2
- 241001500343 Influenzavirus C Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 241000282887 Suidae Species 0.000 abstract description 32
- 206010069767 H1N1 influenza Diseases 0.000 abstract description 7
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 abstract description 7
- 206010022000 influenza Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 244000052637 human pathogen Species 0.000 abstract description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract description 2
- 241000725681 Swine influenza virus Species 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 50
- 239000000243 solution Substances 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000002299 complementary DNA Substances 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 22
- 150000002500 ions Chemical class 0.000 description 18
- 241000282898 Sus scrofa Species 0.000 description 17
- 239000000203 mixture Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 241000282339 Mustela Species 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 230000035931 haemagglutination Effects 0.000 description 10
- 238000005352 clarification Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 208000037799 influenza C Diseases 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000005336 safety glass Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001308709 unidentified virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/385,004 | 2012-01-27 | ||
| US13/385,004 US9278999B2 (en) | 2012-01-27 | 2012-01-27 | Influenza C virus and vaccine |
| PCT/US2013/023441 WO2013112995A1 (en) | 2012-01-27 | 2013-01-28 | Influenza c virus and vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014134850A RU2014134850A (ru) | 2016-03-20 |
| RU2656186C2 true RU2656186C2 (ru) | 2018-05-31 |
Family
ID=47714564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014134850A RU2656186C2 (ru) | 2012-01-27 | 2013-01-28 | Вирус гриппа с и вакцина |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9278999B2 (enExample) |
| EP (1) | EP2807184A1 (enExample) |
| JP (1) | JP6257529B2 (enExample) |
| CN (1) | CN104203972A (enExample) |
| AU (1) | AU2013211833B2 (enExample) |
| BR (1) | BR112014018278B1 (enExample) |
| CA (1) | CA2862328C (enExample) |
| HK (1) | HK1201283A1 (enExample) |
| MX (1) | MX360831B (enExample) |
| NZ (1) | NZ629378A (enExample) |
| PH (1) | PH12014501688A1 (enExample) |
| RU (1) | RU2656186C2 (enExample) |
| WO (1) | WO2013112995A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015000789A (es) * | 2012-07-19 | 2015-05-07 | Zoetis Llc | Composiciones de virus de la gripe bovina. |
| AR111770A1 (es) | 2017-05-05 | 2019-08-21 | Elanco Us Inc | Vacuna para enfermedad respiratoria bovina |
| CN111363855A (zh) * | 2020-04-30 | 2020-07-03 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 一种同时检测a、d型流感病毒的成套试剂、试剂盒及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2428476C1 (ru) * | 2010-06-21 | 2011-09-10 | Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) | Реассортантный штамм вируса гриппа rn 1/09-swine a(h7n1) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004161781A (ja) * | 1992-03-03 | 2004-06-10 | Dai Ichi Seiyaku Co Ltd | 経口ワクチン |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| CA2671869A1 (en) * | 2006-12-15 | 2008-06-26 | Schering-Plough Ltd. | Method for replicating influenza virus in culture |
| TW200927928A (en) | 2007-09-24 | 2009-07-01 | Nobilon Internat B V | Inactivated influenza vaccine |
| US20090110698A1 (en) * | 2007-10-31 | 2009-04-30 | Newport Laboratories, Inc. | Method of determining vaccine compliance |
-
2012
- 2012-01-27 US US13/385,004 patent/US9278999B2/en active Active
-
2013
- 2013-01-28 AU AU2013211833A patent/AU2013211833B2/en not_active Ceased
- 2013-01-28 CA CA2862328A patent/CA2862328C/en active Active
- 2013-01-28 NZ NZ629378A patent/NZ629378A/en not_active IP Right Cessation
- 2013-01-28 RU RU2014134850A patent/RU2656186C2/ru active
- 2013-01-28 CN CN201380012424.3A patent/CN104203972A/zh active Pending
- 2013-01-28 BR BR112014018278-7A patent/BR112014018278B1/pt active IP Right Grant
- 2013-01-28 JP JP2014554928A patent/JP6257529B2/ja active Active
- 2013-01-28 WO PCT/US2013/023441 patent/WO2013112995A1/en not_active Ceased
- 2013-01-28 MX MX2014009022A patent/MX360831B/es active IP Right Grant
- 2013-01-28 HK HK15101817.2A patent/HK1201283A1/xx unknown
- 2013-01-28 EP EP13704305.5A patent/EP2807184A1/en not_active Ceased
-
2014
- 2014-07-24 PH PH12014501688A patent/PH12014501688A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2428476C1 (ru) * | 2010-06-21 | 2011-09-10 | Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) | Реассортантный штамм вируса гриппа rn 1/09-swine a(h7n1) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации |
Non-Patent Citations (3)
| Title |
|---|
| HIROSHI KIMURA et al., Interspecies transmission of influenza C virus between humans and pigs, Virus research, 1997, Vol.48, pp.71-79. * |
| MARGARET HESSEN, In the clinic. Influenzae, Annals of internal medicine, 03.11.2009, pp.1-16. * |
| MARGARET HESSEN, In the clinic. Influenzae, Annals of internal medicine, 03.11.2009, pp.1-16. HIROSHI KIMURA et al., Interspecies transmission of influenza C virus between humans and pigs, Virus research, 1997, Vol.48, pp.71-79. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015506949A (ja) | 2015-03-05 |
| AU2013211833A1 (en) | 2014-09-18 |
| CN104203972A (zh) | 2014-12-10 |
| BR112014018278A2 (pt) | 2019-04-02 |
| US20130195915A1 (en) | 2013-08-01 |
| HK1201283A1 (en) | 2015-08-28 |
| AU2013211833B2 (en) | 2017-09-14 |
| CA2862328C (en) | 2021-08-31 |
| PH12014501688A1 (en) | 2014-10-20 |
| NZ629378A (en) | 2017-06-30 |
| CA2862328A1 (en) | 2013-08-01 |
| RU2014134850A (ru) | 2016-03-20 |
| BR112014018278B1 (pt) | 2023-01-17 |
| WO2013112995A1 (en) | 2013-08-01 |
| US9278999B2 (en) | 2016-03-08 |
| EP2807184A1 (en) | 2014-12-03 |
| MX360831B (es) | 2018-11-16 |
| JP6257529B2 (ja) | 2018-01-10 |
| MX2014009022A (es) | 2015-03-03 |
| AU2013211833A2 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Polatoğlu et al. | COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies | |
| Aileni et al. | Biotechnological perspectives to combat the COVID-19 pandemic: precise diagnostics and inevitable vaccine paradigms | |
| RU2656186C2 (ru) | Вирус гриппа с и вакцина | |
| CN114835778A (zh) | 一种h9n2亚型aiv mhc b2限制性表位肽及其应用 | |
| TWI702293B (zh) | 用於a型流感病毒及b型流感病毒檢測之方法 | |
| Fereidouni et al. | Failure of productive infection of Mallards (Anas platyrhynchos) with H16 subtype of avian influenza viruses | |
| CN118957165B (zh) | 用于检测甲型流感病毒的探针组合、试剂盒及检测方法 | |
| WO2021214766A1 (en) | Methods of diagnosing viral infections and vaccines thereto | |
| Al-Jaf et al. | Rapid, inexpensive methods for exploring SARS CoV-2 D614G mutation | |
| RU2511440C2 (ru) | Способ количественного определения фиксированного вируса бешенства штамма "москва 3253" | |
| RU2464312C1 (ru) | Реассортантный штамм вируса гриппа rn2/57-human a(h7n2) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации | |
| Qin et al. | Subtyping animal influenza virus with general multiplex RT-PCR and Liquichip high throughput (GMPLex) | |
| Patankar et al. | Development of RT-PCR based diagnosis of SARS-CoV-2 | |
| RU2361924C1 (ru) | Способ обнаружения вируса гриппа а подтипа h5n1 | |
| Kareche et al. | Equine influenza outbreak in Eastern of Algeria in 2021: The first introduction of Florida Clade 1 to Maghreb area | |
| Aileni et al. | Biotechnological perspectives to combat the COVID-19 pandemic: precise diagnostics and inevitable vaccine paradigms. Cells. 2022; 11: 1182 | |
| WO2016210097A1 (en) | Novel equine parvovirus and uses thereof | |
| Yang et al. | Diagnosis of Ebola virus disease: progress and prospects | |
| US20240327822A1 (en) | Materials and methods to comprehensively define adaptive immune responses | |
| Taghizadeh et al. | COVID-19; History, Taxonomy, and Diagnostic Molecular and Immunological Techniques | |
| Kaore et al. | Laboratory diagnosis of novel H1N1 virus | |
| Eromon | Comparative Assessment of SARS-CoV-2 Diagnostics in Nigeria | |
| Resendes | Development of an Aptamer-functionalized Magnetic Particle Sample Purification Protocol for the Plasmonic Polymerase Chain Reaction Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 | |
| Ezzikouri et al. | SARS-CoV-2 Infection Elicits A Greater Humoral Immune Response In The Second Wave Than The First Wave In Morocco | |
| Maharjan | Validation of Saliva Biospecimen: an alternative to Nasopharyngeal Swab for detection of SARS-CoV-2 using RT-PCR |